Eyepoint Pharmaceuticals Inc (EYPT) - Total Liabilities
Based on the latest financial reports, Eyepoint Pharmaceuticals Inc (EYPT) has total liabilities worth $51.51 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Eyepoint Pharmaceuticals Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Eyepoint Pharmaceuticals Inc - Total Liabilities Trend (2000–2024)
This chart illustrates how Eyepoint Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see EYPT total assets.
Eyepoint Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Eyepoint Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Legato Merger Corp. III
NYSE MKT:LEGT
|
USA | $7.04 Million |
|
Shanghai Hile Bio-tech
SHG:603718
|
China | CN¥408.00 Million |
|
XinJiang GuoTong Pipeline Co Ltd
SHE:002205
|
China | CN¥3.40 Billion |
|
Biodesix Inc
NASDAQ:BDSX
|
USA | $86.18 Million |
|
Molson Coors Canada Inc
TO:TPX-B
|
Canada | CA$13.95 Billion |
|
Zorlu Enerji Elektrik Uretim AS
IS:ZOREN
|
Turkey | TL73.96 Billion |
|
WATERDROP INC.ADS/10 CL.A
F:717
|
Germany | €2.56 Billion |
|
Optimum Communications, Inc.
NYSE:OPTU
|
USA | $33.59 Billion |
Liability Composition Analysis (2000–2024)
This chart breaks down Eyepoint Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EYPT net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eyepoint Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eyepoint Pharmaceuticals Inc (2000–2024)
The table below shows the annual total liabilities of Eyepoint Pharmaceuticals Inc from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $81.96 Million | -7.76% |
| 2023-12-31 | $88.86 Million | +5.80% |
| 2022-12-31 | $83.99 Million | +6.32% |
| 2021-12-31 | $78.99 Million | +7.95% |
| 2020-12-31 | $73.18 Million | +13.20% |
| 2019-12-31 | $64.64 Million | +7.77% |
| 2018-12-31 | $59.98 Million | +1023.07% |
| 2017-12-31 | $5.34 Million | -50.26% |
| 2016-12-31 | $10.74 Million | +19.32% |
| 2015-12-31 | $9.00 Million | +16.16% |
| 2014-12-31 | $7.75 Million | -9.38% |
| 2013-12-31 | $8.55 Million | +22.81% |
| 2012-12-31 | $6.96 Million | -28.09% |
| 2011-12-31 | $9.68 Million | -2.94% |
| 2010-12-31 | $9.97 Million | -26.47% |
| 2009-12-31 | $13.56 Million | -22.23% |
| 2008-12-31 | $17.44 Million | -13.71% |
| 2007-12-31 | $20.21 Million | -35.63% |
| 2006-12-31 | $31.40 Million | +1919.22% |
| 2005-12-31 | $1.56 Million | 0.00% |
| 2004-12-31 | $1.56 Million | +15.46% |
| 2003-12-31 | $1.35 Million | +128.90% |
| 2002-12-31 | $588.38K | +303.71% |
| 2000-12-31 | $145.74K | -- |
About Eyepoint Pharmaceuticals Inc
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib… Read more